

## Chairs and Speakers Biographies

### Amjad Zafar

*Jinnah Hospital, Lahore, Pakistan*



I am an Assistant Professor Oncology at Jinnah hospital, Lahore, which is a tertiary care set up in a city of around 10 million people and caters to thousand plus patients per year in terms of its Opd and indoor services. I also am visiting consultant oncology in Hameed Latif hospital and Pakistan Kidney and Liver institute, both are tertiary care set

ups having multiple specialities and later is a transplant institute as well.

### Carmino Antonio De Souza

*Hematology, Health Secretary of Campinas City - São Paulo State and Director of Hematology and Hemotherapy Brazilian Association (ABHH), Brazil*



Professor Carmino Antonio De Souza graduated in Medicine in 1975 with, Medical Residency in Internal Medicine and Hematology and Hemotherapy from 1976-1979, Ph.D. in Medicine and Medical Clinic in 1987, Free Professor in 1996, and Full Professor since 2001 with the Department of Internal Medicine of the Faculty of Medical Sciences - Uni-

versity of Campinas (UNICAMP). He completed his postdoctoral studies at the Department of Hematology, Hospital San Martino, University of Genoa, Italy, between 1997 and 1998 in bone marrow transplantation and malignant lymphomas. Onco-Hematologist, working on malignant lymphomas, chronic myeloid leukemia, and bone marrow transplantation. It has about 420 complete articles published in scientific journals, mainly in English, more than 1200 abstracts in national and international congresses; 30 chapters of scientific books, three non-technical and non-scientific books, 210 articles in physical and virtual newspapers and 45 approved masters and doctoral theses. Citations in the literature: 12200, Index H - 50, and Hi10 - 165 (Google Scholar - 03-08-2023). He is a member and director of the Brazilian Association of Hematology, Hemotherapy, and Cell Therapy (ABHH), the American Society of Hematology (ASH), the Italian-Brazilian Association of Hematology (AIBE), Eurasian Hematology and Oncology Group (EHOG), and of the European Association of Hematology and Hemotherapy (EHA). He was Coordinator of the Hematology and Blood Transfusion Center

of Campinas (Hemocentro) for 14 years (1985-1993 and 2016-2012), Secretary of Health of the State of São Paulo between 1993-1994, Secretary of Health of Campinas between 2013-2020 and Executive Secretary of the State Secretariat of Science, Research, and Development in Health of the State of São Paulo in 2022. Councilor of the FAPESP Board of Directors between 2015-2021 and again for a term of 2022-2028; Full Board member and current President of the Board of Trustees of the Butantan Foundation since December 2022 and Alternate Councilor of the Board of Trustees of the Pró-Sangue Foundation, Hemocentro de São Paulo since June 2022.

### Claudio Cerchione

*IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Italy*



Dr Claudio Cerchione graduated in medicine with honours from the Medical School at the University Federico II of Naples, Italy (July 2008), with a final thesis in Hematology.

During his Fellowship and PhD studies, Dr. Cerchione studied in detail Hematological malignancies, and his main research topics are Acute Leukemias

and Multiple Myeloma. He started his collaboration in Hematology Department, AOU Federico II, Naples, Italy, in 2006, and there he completed with honours his Fellowship in July 2014 and his PhD program in May 2017.

Since 2018, he works in Hematology Unit of Istituto Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST) IRCCS, where he is Head of Myeloma Research Group and Principal Investigator of many clinical trials company sponsored and non-company sponsored.

He has spent international research experiences in Friedrich-Wilhelms Universität, Bonn, Germany, in Universidade de Coimbra, Portugal, collaborating in their clinical and research projects, and in MD Anderson Cancer Center, Houston, USA, where he has been nominated International Ambassador of SOHO (Society of Hematologic Oncology).

He is member of the editorial boards of many scientific journals, or Reviewer for several highly cited international journals and member of several international societies and President of Society of Hematologic Oncology Italy (SOHO Italy).

In 2018/2019 he was nominated by EHA as one of the winners of Clinical Research Training in Hematology.

He is author/co-author of more than one hundred papers in peer-reviewed international journals.

**Deniz Tuğcu**

*Istanbul University, Istanbul School of Medicine, Departement of Pediatric Hematology-Oncology, Istanbul, Türkiye*

**EDUCATIONAL BACKGROUND:**

Istanbul University, Istanbul School of Medicine, 1993

SSK Bakırköy Maternity and Children, Training and Research Hospital, 1998, specialization in pediatrics  
Istanbul University, Istanbul School of Medicine, 2008, specialization in Pediatric Hematology-Oncology

**THESIS**

**Thesis in Pediatrics:** Respiratory Syncytial Virus Infections in Childhood: Predisposing Factors and Hematological Findings.  
Supervisor: Clinical Chief Dr. Cengiz Yavuz

**Thesis in Pediatric Hematology-Oncology:** The Relationship Between Plasminogen Activator Inhibitor-1 (PAI-1), Vitronectin Levels and Risk Factors in Childhood Solid Tumors (Supervisor: Prof. Dr. Omer Devencioglu)

**ACADEMIC TASKS**

Research assistant in pediatrics: 1993-1998: SSK Bakırköy Maternity and Children, Training and Research Hospital  
Pediatrician: 1998-2005: SSK Bakırköy Maternity and Children, Training and Research Hospital

Research assistant in Pediatric Hematology-Oncology: 2005-2008: Istanbul University, Istanbul School of Medicine  
Pediatric hemato-oncology: 2008-2015: Kanuni Sultan Suleyman Training and Research Hospital

Associate Professor: 2015-2021: Istanbul University, Istanbul School of Medicine

Professor: Since 2021

**INTERESTED AREAS:**

Pediatric Hematology-Oncology  
Pediatric Solid Tumors  
Hemostasis  
Therapeutic Apheresis  
Pediatric Bone Marrow Transplantation

**ADMINISTRATIVE TASKS:**

Istanbul Pediatric Oncology Group, Tumor Meeting Secretariat (2008-2015)

Turkish Pediatric Hematology Association, Histiocytosis Subgroup membership (2010-2012 and 2018-2020)

Turkish Pediatric Hematology Association, Febrile Neutropenia Subgroup membership (2012-2014 and 2016-2018 and 2018-2020)

Turkish Pediatric Hematology Association, Febrile Neutropenia Subgroup chair (2023)

Pediatrics qualification board assessment and evaluation commission member: Since 2020

**MEMBERSHIPS TO SCIENTIFIC ORGANIZATIONS:**

Turkish Pediatric Oncology Group  
Turkish Society of Pediatric Hematology

**Hematology Specialty Association**

Therapeutic Apheresis Training and Responsible Physician

**Drew Provan**

*Emeritus Reader in Autoimmune Haematology at Barts and The London School of Medicine and Dentistry, London, UK.*



Drew Provan is currently Emeritus Reader in Autoimmune Haematology at Barts and The London School of Medicine and Dentistry, London, UK.

Dr. Provan studied molecular genetics at Leicester University before studying medicine. After junior medical posts in the UK, he undertook research at The Dana-Farber Cancer Institute from

1993-4 on an American Traveling fellowship awarded by the Medical Research Council.

His main area of interest is immunohaematology which includes immune thrombocytopenia (ITP), neutropenia and haemolytic anaemia. Dr. Provan established the UK ITP Registry, a clinical and laboratory database of patients with ITP. This facilitates the collection of clinical information related to adults with ITP throughout the UK, in addition to allowing for DNA samples to be obtained for genetic analysis.

Dr. Provan, along with International colleagues, published the Revised International Consensus guidelines for the diagnosis and management of ITP published in Blood Advances in 2019. The consensus document is currently being updated and will be published late 2023.

He has written numerous peer-reviewed papers, book chapters, and has authored several medical books including Molecular Hematology (Wiley), Oxford Handbook of Clinical Haematology and Oxford Handbook of Clinical and Laboratory Investigation, and the ABC of Clinical Haematology (BMJ books).

**Gerardo Musuraca**

*Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l.*

*Via Piero Maroncelli, 40 - 47014 Meldola (FC), Italy*

*High School Graduation at "Liceo Ivo Olivetti" in 1995*

*M.D. with full marks, cum laude at University of Bologna in 2001*

**EXPERIENCES**

Attends as a border student the Institute of Hematology "L. & A. Seragnoli"  
Chief: Prof. M. Baccarani, from 2001 to 2002.

Since 2001 attends as post doctoral fellow in the Institute of Hematology "L. & A. Seragnoli"

Chief: Prof. M. Baccarani.

From June to July 2004 and May 2005: student to Regent school of Oxford (British Council) 2005-Degree with honours at the school of specialization in Hematology at the University of Bologna. in the the Institute of Hematology "L. & A. Seragnoli"

Since January 2006 PhD student in clinical and experimental Hematology at the University of Bologna. in the the Institute of Hematology "L. & A. Seragnoli"

2009 degree with honours PhD in clinical and experimental Hematology at the University of Bologna. in the the Institute of Hematology "L. & A. Seragnoli"

Since 2007 Clinical activity and research at IRCCS Istituto scientifico Romagnolo "Dino Amadori" IRST, Meldola

Abstracts Reviewer and moderator at session 625 lymphoma, preclinical and biologic agents of American Society of Hematology (ASH) meeting December 2011

From January to March 2014 Master in medical direction at Bocconi's University, Milan.

From September 2017, degree of high specialization in Lymphomas at IRCCS Istituto scientifico Romagnolo "Dino Amadori" IRST, Meldola

From November 2019 to now, Chief of the Lymphoma unit and Director of the Hematology Unit at Istituto scientifico Romagnolo "Dino Amadori" IRCCS IRST, Meldola

From February 2022: Contract professor at University of Bologna

From May 2022 to now: Board representative of the specialization school in Hematology, University of Bologna

Member of Italian Lymphoma Foundation (FIL)

AUTHOR of more than 60 PRINTED and indexed PUBLICATIONS.

CURRENTLY REVIEWER FOR THE FOLLOWING JOURNALS:

Cancers,

Current oncology,

Biomedicines

BMC pulmonary medicines

International Journal of Molecular Sciences

GUEST EDITOR AND SPECIAL ISSUE EDITOR FOR:

International Journal of Molecular science

SPECIAL ISSUE: "Immunology in Lymphoma and Lymphoproliferative Diseases"

H-index: 22

ORC ID: 0000-0003-1947-1032

SCOPUS ID: 6602731241

Since 2001 involved in multicenter national and international clinical trials performed in onco-hematology.

#### **Hanan Hamed**

Ain Shams University, Cairo, Egypt



Professor of Internal Medicine and Clinical Hematology Faculty of Medicine Ain Shams

University from October 2004 - till now.

Member of Hematology Board at Faculty of Medicine Ain Shams University.

Member of Bone Marrow Transplantation Board at Faculty of Medicine Ain Shams University.

Head of Internal Medicine and Clinical Hematology Unit Ain Shams University Specialized

Hospital ASUSH Cairo - Egypt. Till February 2019.

Member of scientific committee of Internal Medicine and clinical Hematology in Supreme

Council of Universities in Egypt.

Vice president of Egyptian society of Hematology.

#### *Qualifications:*

MB Bch, December 1983 Faculty of Medicine Ain Shams University

M Sc Internal Medicine, April 1988 Faculty of Medicine Ain Shams University

M D Internal Medicine, April 1994 Faculty of Medicine Ain Shams University

Full training program in "Medical Response to Nuclear Accidents" in collaboration with

Radiation Emergency Assistance Centre/ Training Site REACTS - Oak Ridge Institute of Science 1994

#### *Member of:*

American Society of hematology ASH

European Hematological Association EHA

International Society of Hematology ISH

Society of Hematologic Oncology SOHO

International Union of Angiology IUA

Egypt representative and ambassador Eurasian hematooncology group EHO.

Pan-Arab hematology association

Founder and Adult hemato-oncology director in Middle East and North Africa Hematology

League MENAHL.

Egyptian Hemato-oncology group EHO

Egyptian Society of Hematology ESH

Egyptian Group of Hemostasis and Thrombosis

Egyptian Society of Oncology

Egyptian Society of Vascular Diseases and Surgery

#### **Hasan Fatih Çakmaklı**

Department of Pediatric Hematology, Ankara University, Ankara, Türkiye



Hasan Fatih Çakmaklı, MD, is an assistant professor in Ankara University Department of Pediatric Hematology. After he graduated from Hacettepe University Faculty of Medicine in 2003, he completed his residency in Hacettepe University Department of Pediatrics in 2009. He worked as an elected pediatric chief resident in 2007-2008. Afterwards, he

did pediatric hematology and oncology residency in Ankara University between 2009-2012. After completing obligatory service in Şanlıurfa Children's Hospital (October 2013-February 2014) and in Ankara Children's Health and Diseases, Hematology and Oncology Education and Research Hospital (February 2014-September 2015), he worked as a visiting scholar at Emory University Pediatric Hematology Department laboratory in a project on



thalassemia mice model and oxidative stress, and did also clinical observership at Emory University Department of Pediatric Hematology (with the support of Turkish National Scientific Council / 2219 Postdoctoral Research Fellowship award) (September 2015-September 2016). Then, he worked as a specialist in pediatric hematology and oncology in Ankara Children's Health and Diseases, Hematology and Oncology Education and Research Hospital until he joined Ankara University Department of Pediatric Hematology and Oncology as a specialist in February 2018. In September 2021 until now, he has been working as an assistant professor in the same department. His main interests are leukemia, thrombosis, and bleeding diathesis in childhood.

#### **Lv Lulu**

M.D., CEO of Juventas Cell Therapy Ltd.



Dr. Lv founded Juventas as Chief Executive Officer in 2018. Under her leadership, the company's first CAR-T (chimeric antigen receptor T cells) product, CNCT19 (Inaticabtagene Autoleucel) Injection, is approaching commercialization. Dr. Lv has constructed an innovative pipeline strategy system fueled by CAR platform, iPSCs platform, and gene-

editing platform, for pioneering new drugs development. The strong cooperation with national scientific institutes ensures our indication coverage spanning a broad range of therapeutics fields, from hematology, solid tumor, to autoimmune disease. Dr. Lv has dedicated herself to developing innovative and accessible therapies for patients in need.

Dr. Lv Lulu has been focusing on oncology scientific research and innovative drug development for more than 20 years. Before leading Juventas, Dr. Lv held executive and significant positions in Novartis, Genzyme, Roche, AstraZeneca, and Merck. She has garnered a wealth of experience in R&D, regulatory affairs, and commercialization of cellular immunotherapy products. She has played indispensable roles in the R&D, regulatory affairs, market expansion, and commercialization of innovative anti-cancer products such as Gleevec®, Herceptin®, Tagrisso®, and Keytruda®.

Prior to her new drug life-cycle management career in multinational pharmaceutical companies, she mainly undertook the clinical and scientific research on hematopoietic and mesenchymal stem cells. In 2001, Dr. Lv participated in the first umbilical cord blood transplantation in China for the treatment of childhood leukemia. She pioneered and established the domestic technology of isolating mesenchymal stem cells from the umbilical cord in 2004. In the following year, she continued her research on hematopoietic cell transplantation and mesenchymal stem cells at Westchester Medical Center of New York Medical College. Dr. Lv published various papers in domestic and international journals. She received her Ph. D. for clinical medicine (Internal Medicine, Hematology) in 2006.

#### **Melissa Hudson,**

Member, St. Jude Faculty

Director, Cancer Survivorship Division

Associate Director, Population Sciences

The Charles E. Williams Endowed Chair of Oncology-Cancer Survivorship



Melissa M. Hudson, MD, is currently a Member and Director of the Cancer Survivorship Division in the Department of Oncology and holds the Charles E. Williams Endowed Chair of Oncology-Cancer Survivorship. She directs the After Completion of Therapy Clinic and serves as the Principal Investigator of the St. Jude Lifetime Cohort Study.

Dr. Hudson works collaboratively with multidisciplinary investigators in national and international initiatives evaluating biomedical and psychosocial outcomes among childhood cancer survivors and translating data from health outcomes research into evidence-informed clinical practice guidelines and interventions to improve the quality and duration of survival after childhood cancer.

#### **Moshe Mittelman**

Tel Aviv Sourasky Medical Center



**Moshe Mittelman MD**, completed his term as the Chairman, Department of Medicine, at the Tel Aviv Sourasky (Ichilov) Medical Center, in 2020. He continues as a senior consultant for Hematology. He is also Professor Emeritus, in medicine and hematology, the School of Medicine, Tel Aviv University.

Among other tasks, Prof. Mittelman serves as the Chief Technology Officer, Scientific-Medical Director and a consultant for a biotech fund (TALENT) and investors, and is involved in several biotech start-ups companies. In 2019 he established, and continues to run a hematology-oncology service in the LISOD Oncology Center, in Kiev, Ukraine.


Professor Mittelman graduated from the Faculty of Medicine, Tel Aviv University in 1976, and completed a Residency in Internal Medicine at the Hasharon Hospital, Petah-Tikva, Israel. He later undertook a Combined Clinical and Research Fellowship Programme in Hematology and Oncology at the George Washington University Medical Center, Washington DC, USA, and The National Institutes of Health (NIH), Bethesda, USA, before returning to Israel in 1989. On returning to Israel, he served as Deputy-Director (1989-1994) and then Director (1994-2003), Department of Medicine B, Hasharon Hospital. In 2003 he moved to Ichilov Medical Center, to serve as the Chief of Medicine A and the Chairman of The Department of Medicine (9 wards, 360 beds), till 2020.

Professor Mittelman's research interests include basic and clinical aspects of stem cell disorders such as myelodysplastic

syndromes (MDS) and myeloproliferative neoplasms (MPN), multiple myeloma, basic and clinical effects of erythropoietin, translational research of malignant hematology and applying digitalization into practical medicine. He published more than 200 professional papers summarizing his clinical and research activities in prestigious journals such as *Blood*; *Haematologica*; *British Journal of Haematology*; *American Journal of Hematology*; *Lancet Haematology*, *Annals of Hematology*; *Leukemia*; *Leukemia Research*; *Annals of Internal Medicine*; *Journal of Clinical Oncology*, and others. He was a member of the editorial board of *European Journal of Internal Medicine*, and currently serves in the editorial board of the *Israel Medical Association Journal (IMAJ)*, *Journal of Clinical Medicine* (also co-editor) and *Haematologica*, as well as a reviewer for the top journals in hematology, oncology and medicine. Over the years Moshe has served in academic and public duties, including Chairman, the admission committee for medical students, TAU; The National Committee for new technologies in public health ("Vaadat Sal"); BOD, Israel Cancer Association (he is currently the Acting Chairman of the Association, Aguda); Board of Trustees, The Academic College Tel Aviv-Jaffa; Secretary & Chairman, Israel Society of Internal Medicine; President, Israel Society of Hematology; The national committee for clinical trials (Helsinki), Israel Ministry of Health; and Chairman, the Scientific Board, International MDS Foundation.

#### **Murat Ozbalak**

*Istanbul University Istanbul Medical Faculty*



Murat Ozbalak, M.D., was born in 1984 in Istanbul. He was graduated from Istanbul University Cerrahpasa Medical Faculty English Program in 2009. He completed his residency in Istanbul University Cerrahpasa Medical Faculty in 2015. He performed his hematology fellowship in Istanbul University Istanbul Medical Faculty between 2018 and 2021.

He is PhD candidate in the immunology department of Istanbul University Aziz Sancar Experimental Medicine Institute. He has been associate professor of hematology since June 2023, and he works in Başakşehir Çam ve Sakura City Hospital.

#### **Nurşah Eker**

*Marmara University Faculty of Medicine, İstanbul, Türkiye*



She is Assistant Professor in Pediatric Hematology Oncology and Bone Marrow Transplantation at the Marmara University. Asst. Prof. Eker trained in pediatrics at the Şişli Etfal Education and Research Hospital and completed a fellowship in pediatric hematology and oncology at the Akdeniz University

Faculty of Medicine. Asst. Prof. Eker has been working in Pediatric Hematology Oncology and Bone Marrow Transplantation Unit at the Marmara University Faculty of Medicine since 2018.

#### **Pia Raanani**

*Tel Aviv University Faculty of Medicine, Israel*



Prof. Pia Raanani MD is Head of the Division of Hematology at the Rabin Medical Center. She is Full Professor in Hematology at the Tel-Aviv University.

Prof. Raanani trained in hematology at the Sheba Medical Center and completed a fellowship in CML at the Hammersmith Hospital, Royal Postgraduate Medical School in London. In 2007 she

established the Hemato-oncology Hospitalization Unit at the Davidoff Cancer Center. Prof. Raanani was Head of the Department of Hematology of the Faculty of Medicine Tel-Aviv University between 2010-2014 and has been Head of the Research Funds Committee of the Sackler School of Medicine since 2014.

Prof. Raanani is on the Editorial board of several international hematology journals. Since 2015 she has served as Ambassador for Israel of the MD Anderson Society of Hematologic Oncology (SOHO). Since July 2017 she is Editor-in-Chief of the journal *Acta Haematologica*.

Prof. Raanani is a co-author of 265 articles as well as chapters in books. During the last years, she has chaired several international scientific meetings in the field of hemato-oncology.

#### **Salam Alkindi**

*BA, MB, BCh, BAO, DME, MSc, FRCP Professor, senior consultant Department of haematology Sultan Qaboos university-Muscat Oman*




Following my graduation from Trinity college- Dublin Ireland, in 1993, I have completed my general medicine as well as haematology/ oncology training in Dublin, Ireland and Fred Hutch cancer centre in Seattle USA, where I did my training in Bone marrow transplant. In 1999 I have joined Sultan Qaboos University and in 2005 I was appointed as

head of department of haematology for 10 years. Previously also I held the position of deputy director of Sultan Qaboos university hospital for clinical affairs (clinical director) for 5 years. Research interests include sickle cell disease, chronic leukaemia and autoimmune disorders with over 120 articles published in international peer reviewed journals including *NEJM*, *haematologica*, and *blood*. I am founder of Oman hereditary blood disorders association, and currently deputy chairman.

**Süheyla Ocak**

Department of Pediatric Hematology and Oncology at Cerrahpasa Medical

**General Information**

Current position: Assoc. Prof. of Pediatric Hematology and Oncology,  
Clinical Affiliation: Department of Pediatric Hematology and Oncology at Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa 34098 Fatih, Istanbul  
Homepage: <https://avesis.iuc.edu.tr/suheylaocak>

ORCID: <https://orcid.org/0000-0001-7479-7444>

Email: suheylaocak@iuc.edu.tr

**Curriculum vitae****Education**

**2009-2012** Fellow, Department of Pediatric Hematology and Oncology, Hacettepe University Medical Faculty, Ankara, Türkiye  
**2002-2008**- Resident, Department of Pediatrics, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul - Türkiye  
**1996-2002**- MD, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul - Türkiye

**Degrees and Professional Experience**

**2019**- Associate Prof. of Pediatric Hematology and Oncology, Department of Pediatric Hematology-Oncology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye.  
**2016-2019**- Attending Pediatric Hematologist and Oncologist, Department of Pediatric Hematology-Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul Türkiye  
**2016**- (January 31-September 31) Pediatric Hematologist-Oncologist, Pediatric Bone Marrow Transplantation Unit, Yenyüzyıl University, Istanbul, Türkiye.  
**2007**- (January 31- April 01) Observer, Pediatric Hematology and Oncology, Texas Children Hospital

**Awards and Scholarships**

**2008**- Turkish Pediatric Oncology Group, Research Award  
**2022**- Turkish Archives of Pediatrics Journal, Nil Arisoy Award for Original Article

**Courses/Certificates**

**2021**- Certificate of Therapeutic Apheresis, Turkish Ministry of Health  
**2018**- Masterclass of Blood Banking and Transfusion Medicine, Turkish Society of Hematology  
**2019**- SIREDO-1, Course on adolescent and young adult Sarcomas, Paris, France.  
**2012**- ESO- European School of Oncology, Pediatric Oncology Masterclass, Rome, Italy

**Memberships**

Turkish Society of Hematology  
Turkish Pediatric Oncology Group (TPOG)

Turkish Society of Pediatrics (TPK)  
European Society for Pediatric Oncology (SIOPE)  
European Consortium of Histiocytosis (ECHO)

**Main Research Interests/Activities**

Pediatric Lymphomas  
Histiocytoses  
Pediatric Solid Tumors

**Tuba Eren**

Trakya University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology-Oncology Edirne, Türkiye




Tuba Eren was graduated from Gazi University, Medical Faculty in 1999, and completed her pediatric residency program at Sami Ulus Training and Research Hospital, in 2005. After three years of practice as a pediatrician, she completed her pediatric oncology residency program at Ankara Oncology Training and Research Hospital in 2012.

Dr. Eren works at the Trakya University, Faculty of Medicine, Department of Pediatric Hematology-Oncology since 2012.

**Umberto Vitolo**

Candiolo Cancer Institute-Fondazione Piemontese per l'Oncologia-IRCCS, Candiolo (Turin), Italy



Umberto Vitolo, MD, is Hematology Consultant at Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo (Torino), Italy since January 2020 till now. In the past he was the Director of the Haematology Section of the Department of Oncology and Haematology at the University Hospital "Città della Salute e della Scienza"

in Turin, Italy up to November 30th 2019. He received his MD degree from the University of Turin in 1977; he was trained in haematology at the University of Pavia, and in clinical immunology at the University of Florence, Italy, then worked as a clinical research fellow in the haematology/oncology section of the Cancer Research Center, University of Chicago, IL, USA. He has also been Professor of Haematology at the post-graduate school of haematology of the University of Turin since 2005.

Dr Vitolo's research interests include haematological malignancies, chemotherapy, and biological therapies; he has a special interest in the biology and treatment of malignant lymphoma and is actively involved in clinical research in malignant lymphoma. He is currently leading and being involved in several cooperative multicentre trials in follicular and diffuse large cell lymphoma testing novel combination of chemoimmunotherapy, biological agents, bispecific antibodies and others.

He is member of the Italian Society of Hematology, Italian Society of Experimental Hematology and American Society of Hematology. He is elected member of the Accademy of Medicine of Torino. He is member of the expert panel for the Diffuse Large B-cell Lymphoma guidelines for the European Society for Medical Oncology and for the European Hematology Association. He was Chairman of the Italian Lymphoma Intergroup from 2007 to 2010 and President of the Italian Lymphoma Foundation from 2010 to October 2011 and now member of board of directors of the Foundation. He has authored more than 250 papers in peer-reviewed journals.

#### **Zeba Aziz**

Prof. Dr Zeba Aziz is a Renowned Medical Oncologist in Pakistan. She has been the Head of the Medical Oncology Depart-

ment in Hameed Latif Hospital, Lahore, Pakistan since 1994, where she is also the Program Director for the Medical Oncology Fellowship. She previously served as a Professor & Head of the Department of Oncology at Jinnah Hospital, Lahore. She has also been the Dean of Medical Oncology for the College of Physicians and Surgeons Pakistan. She is currently the President of the Society of Medical Oncology of Pakistan. Her international activities include being on the steering committee for the Australian & Asia Pacific Oncology Research Development (ACORD) Workshop. She is also a Member of Expert Advisory Panel on Drug Evaluation World Health Organization (WHO) and Member of Expert Advisory Group (EAG) Medicine Patent Pool, Switzerland. She is also a member of She has made contributions to international cancer research through more than 80 peer-reviewed publications primarily on Hematologic malignancy, and breast and ovarian cancers.